Literature DB >> 12588349

Two novel mutations, Q1053H and C1060R, located in the D3 domain of von Willebrand factor, are responsible for decreased FVIII-binding capacity.

Lysiane Hilbert1, Sylvie Jorieux, Valérie Proulle, Rémi Favier, Jenny Goudemand, Armelle Parquet, Dominique Meyer, Edith Fressinaud, Claudine Mazurier.   

Abstract

In type 2N von Willebrand disease (VWD), von Willebrand factor (VWF) is characterized by a markedly decreased affinity for Factor VIII (FVIII), and the mutations responsible are essentially located in the D' domain of VWF. We report the identification, in seven unrelated French families, of two novel type 2N VWD mutations, Q1053H and C1060R (Gln290His and Cys297Arg in mature VWF sequence), in exon 24 of the VWF gene. These missense mutations have been identified in the heterozygous, homozygous or hemizygous states. Using site-directed mutagenesis and transient expression in COS-7 cells, we showed that both mutations, although located in the D3 domain of VWF, outside the tryptic fragment containing the FVIII domain, dramatically decrease the binding of VWF to FVIII. In contrast, the R924Q substitution, which was identified in a patient who was heterozygous for C1060R, was shown to be a polymorphism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12588349     DOI: 10.1046/j.1365-2141.2003.04163.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

1.  Polymorphic variation within the VWF gene contributes to the failure to detect mutations in patients historically diagnosed with type 1 von Willebrand disease from the MCMDM-1VWD cohort.

Authors:  Daniel J Hampshire; George J Burghel; Jenny Goudemand; Laura C S Bouvet; Jeroen C J Eikenboom; Reinhard Schneppenheim; Ulrich Budde; Ian R Peake; Anne C Goodeve
Journal:  Haematologica       Date:  2010-09-17       Impact factor: 9.941

2.  Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A.

Authors:  Yohann Repessé; Catherine Costa; Roberta Palla; Elika Farrokhi Moshai; Annie Borel-Derlon; Roseline D'Oiron; Chantal Rothschild; Amal El-Beshlawy; Mohsen Elalfy; Vijay Ramanan; Peyman Eshghi; Johannes Oldenburg; Anna Pavlova; Frits R Rosendaal; Flora Peyvandi; Srinivas V Kaveri; Sébastien Lacroix-Desmazes
Journal:  Haematologica       Date:  2019-01-31       Impact factor: 9.941

3.  von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels.

Authors:  N Hickson; D Hampshire; P Winship; J Goudemand; R Schneppenheim; U Budde; G Castaman; F Rodeghiero; A B Federici; P James; I Peake; J Eikenboom; A Goodeve
Journal:  J Thromb Haemost       Date:  2010-09       Impact factor: 5.824

4.  The von Willebrand factor D'D3 assembly and structural principles for factor VIII binding and concatemer biogenesis.

Authors:  Xianchi Dong; Nina C Leksa; Ekta Seth Chhabra; Joseph W Arndt; Qi Lu; Kevin E Knockenhauer; Robert T Peters; Timothy A Springer
Journal:  Blood       Date:  2019-01-14       Impact factor: 22.113

5.  Identification and characterization of the elusive mutation causing the historical von Willebrand Disease type IIC Miami.

Authors:  T Obser; M Ledford-Kraemer; F Oyen; M A Brehm; C V Denis; R Marschalek; R R Montgomery; J E Sadler; S Schneppenheim; U Budde; R Schneppenheim
Journal:  J Thromb Haemost       Date:  2016-08-20       Impact factor: 5.824

6.  Noncanonical type 2B von Willebrand disease associated with mutations in the VWF D'D3 and D4 domains.

Authors:  Monica Sacco; Stefano Lancellotti; Mattia Ferrarese; Francesco Bernardi; Mirko Pinotti; Maira Tardugno; Erica De Candia; Leonardo Di Gennaro; Maria Basso; Betti Giusti; Massimiliano Papi; Giordano Perini; Giancarlo Castaman; Raimondo De Cristofaro
Journal:  Blood Adv       Date:  2020-07-28

7.  Cleavage of von Willebrand factor by granzyme M destroys its factor VIII binding capacity.

Authors:  Martine J Hollestelle; Ka Wai Lai; Marcel van Deuren; Peter J Lenting; Philip G de Groot; Tom Sprong; Niels Bovenschen
Journal:  PLoS One       Date:  2011-09-01       Impact factor: 3.240

Review 8.  The molecular genetics of von Willebrand disease.

Authors:  Ergül Berber
Journal:  Turk J Haematol       Date:  2012-12-05       Impact factor: 1.831

9.  Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS.

Authors:  Luciano Baronciani; Ian Peake; Reinhard Schneppenheim; Anne Goodeve; Minoo Ahmadinejad; Zahra Badiee; Mohammad-Reza Baghaipour; Olga Benitez; Imre Bodó; Ulrich Budde; Andrea Cairo; Giancarlo Castaman; Peyman Eshghi; Jenny Goudemand; Wolf Hassenpflug; Hamid Hoorfar; Mehran Karimi; Bijan Keikhaei; Riitta Lassila; Frank W G Leebeek; Maria Fernanda Lopez Fernandez; Pier Mannuccio Mannucci; Renato Marino; Nikolas Nikšić; Florian Oyen; Cristina Santoro; Andreas Tiede; Gholamreza Toogeh; Alberto Tosetto; Marc Trossaert; Eva M K Zetterberg; Jeroen Eikenboom; Augusto B Federici; Flora Peyvandi
Journal:  Blood Adv       Date:  2021-08-10

10.  Von Willebrand Factor Facilitates Intravascular Dissemination of Microsporidia Encephalitozoon hellem.

Authors:  Jialing Bao; Biying Mo; Guozhen An; Jian Luo; Mortimer Poncz; Guoqing Pan; Tian Li; Zeyang Zhou
Journal:  Front Cell Infect Microbiol       Date:  2021-05-21       Impact factor: 5.293

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.